OF
Omega Fund Management, LLC
13F filer · CIK 0001637359Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$186MU.S. long equity reported on 13F
Positions101 new · 1 closed
Net flow last quarter-$19.6MBuys minus sells
Top 10 positions weight100.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202610 positions | |||||
| BTBCAXBicara Therapeutics Inc. | $54.1M | 29.14% | 2.76% | -23.8% | Q3 2024 |
| $45.9M | 24.72% | 2.33% | Not reported | Q1 2021 | |
| $26M | 14.00% | 1.75% | Not reported | Q1 2025 | |
| $25.1M | 13.50% | 4.11% | Not reported | Q3 2025 | |
| $20.6M | 11.11% | 2.93% | Not reported | Q1 2025 | |
| $6.79M | 3.66% | Not reported | Not reported | Q2 2024 | |
| $2.94M | 1.59% | 0.28% | Not reported | Q1 2021 | |
| $2.69M | 1.45% | 4.04% | Not reported | Q3 2025 | |
| $1.52M | 0.82% | 1.31% | Not reported | Q4 2023 | |
| $54.1K | 0.03% | 0.01% | New | Q2 2026 | |
| Q1 2026Reported May 15, 202610 positions | |||||
| BTBCAXBicara Therapeutics Inc. | $47.6M | 29.16% | 3.65% | +8.5% | Q3 2024 |
| $34.7M | 21.25% | 2.33% | Not reported | Q1 2021 | |
| $29.4M | 18.05% | 4.11% | Not reported | Q3 2025 | |
| $20.4M | 12.49% | 1.75% | -25.6% | Q1 2025 | |
| $13.2M | 8.08% | 2.95% | Not reported | Q1 2025 | |
| $5.97M | 3.66% | 1.31% | Not reported | Q4 2023 | |
| $5.31M | 3.26% | Not reported | -63.1% | Q2 2024 | |
| $2.43M | 1.49% | 0.31% | Not reported | Q1 2021 | |
| $2.28M | 1.40% | 4.07% | Not reported | Q3 2025 | |
| $1.91M | 1.17% | 0.30% | Not reported | Q3 2018 | |
| Q4 2025Reported Feb 17, 202611 positions | |||||
| $72.4M | 25.27% | 2.33% | -8.5% | Q1 2021 | |
| $41.2M | 14.37% | 4.11% | Not reported | Q3 2025 | |
| $40.1M | 14.00% | 2.97% | -31.5% | Q1 2025 | |
| BTBCAXBicara Therapeutics Inc. | $37.1M | 12.95% | 3.90% | Not reported | Q3 2024 |
| $36.4M | 12.71% | 2.35% | -16.5% | Q1 2025 | |
| $36M | 12.57% | 2.45% | -2.2% | Q4 2024 | |
| $7.91M | 2.76% | 1.31% | +66.5% | Q4 2023 | |
| $6.38M | 2.23% | Not reported | Not reported | Q2 2024 | |
| $3.43M | 1.20% | 0.32% | Not reported | Q1 2021 | |
| $3.14M | 1.10% | 4.07% | Not reported | Q3 2025 | |
| $2.42M | 0.84% | 0.31% | Not reported | Q3 2018 | |
| Q3 2025Reported Nov 14, 202512 positions | |||||
| $39.1M | 17.59% | 3.20% | Not reported | Q1 2025 | |
| $38.2M | 17.16% | 4.36% | -3.4% | Q1 2025 | |
| $38.1M | 17.13% | 4.15% | New | Q3 2025 | |
| BTBCAXBicara Therapeutics Inc. | $34.8M | 15.66% | 4.04% | Not reported | Q3 2024 |
| $32.7M | 14.69% | 2.61% | -20.0% | Q1 2021 | |
| $25.5M | 11.47% | 2.51% | -33.4% | Q4 2024 | |
| $3.71M | 1.67% | 11.32% | New | Q3 2025 | |
| $3.6M | 1.62% | 1.03% | Not reported | Q4 2023 | |
| $3M | 1.35% | 0.32% | Not reported | Q1 2021 | |
| $2.61M | 1.17% | Not reported | Not reported | Q2 2024 | |
| $1.04M | 0.47% | 0.32% | -87.4% | Q3 2018 | |
| $63.4K | 0.03% | Not reported | -72.1% | Q4 2023 | |
Premium opens every quarter this fund has filed